Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp and Pacritinib in Myelofibrosis
NCT06414681Phase 1Recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Immunotoxins, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tagraxofusp and pacritinib in myelofibrosis (MF), sponsored by University of Kansas Medical Center. Primary endpoints: Spleen Volume Reduction >= 35% at 24 weeks and Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score at 24 weeks. Started Aug 2025; status: recruiting.
02
Drugs
tagraxofusppacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06414681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414681.